A biomarker could help identify patients with lung cancer who are most likely to benefit from treatment with AstraZeneca and Daiichi Sankyo's TROP2-directed drug datopotamab deruxtecan (Dat
Roche has obtained a CE Mark in the EU for a companion diagnostic that can be used to identify patients with HER2-low metastatic breast cancer who may be eligible for trea
Roche has turned to artificial intelligence specialist PathAI to accelerate development of digital pathology technologies that can be used to match patients with drug treatments and s
Shares in Agios Pharma ticked upwards after the FDA awarded breakthrough status to a companion diagnostic to vorasidenib, its experimental drug for brain cancer.